Andarine is a selective non-steroidal androgen receptor (AR) agonist with Ki of 4 nM, and it is tissue selective for the metabolic organ. Phase 3.
It is a potent and tissue-selective androgen receptor modulator (SARM)
Pale Yellow Solid
In vivo, Andarine has an effective metabolic activity, and stimulates the growth of the prostate, seminal vesicle, and levator ani, with ED50 is 0.43 mg/day, 0.55 mg/day, and 0.14 mg/day respectively. This effect is dose dependent. In addition, Andarine acts on FSH, which does not affect some physiological changes caused by castration, and at a dose of 0.5 mg or more per day, partially inhibiting LH production. Andarine was administered to dog intravenously at 0.1, 1, 3, and 10 mg/kg doses, then the total body clearance (CL) decreased from 7.4 mL/min/kg to 3.1 mL/min/kg, the steady-state volume (Vss) was 1.39 L/kg and the half-life was 229 minutes. In addition, Andarine was 10 mg/kg, 1 mg/kg and 0.1 mg/kg, with oral bioavailability of 38%, 62% and 91% respectively. Andarine has tissue selective pharmacological activity and is well treated with 0.5 mg/day concentration, significantly reducing prostate weight to 79.4%.
Andarine is a selective non-steroidal androgen receptor (AR) agonist.
In vitro, Andarine binds to androgen receptors with high affinity with Ki of 4 nM. Moreover, 10 nM Andarine stimulated the transcription adjusted by androgen receptor, up to 93%.